SEC Info - Anika Therapeutics, Inc. - ‘10-K’ for 12/31/10

SEC Info℠

Home

Help

Please Sign In

Anika Therapeutics, Inc. – ‘10-K’ for 12/31/10 – ‘EX-10.35’

On: Wednesday, 3/16/11, at 5:29pm ET · For: 12/31/10 · Accession #: 1157523-11-1610 · File #: 1-14027

  As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

 3/16/11  Anika Therapeutics, Inc.          10-K       12/31/10   10:2.0M                                   Business Wire/FA

Annual Report — Form 10-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Anika Therapeutics, Inc. 10-K                       HTML   1.11M 
 2: EX-10.33    Material Contract                                   HTML     15K 
 3: EX-10.34    Material Contract                                   HTML     15K 
 4: EX-10.35    Material Contract                                   HTML     11K 
 5: EX-10.36    Material Contract                                   HTML     11K 
 6: EX-21.1     Subsidiaries                                        HTML      7K 
 7: EX-23.1     Consent of Experts or Counsel                       HTML      8K 
 8: EX-31.1     Certification -- Sarbanes-Oxley Act - Sect. 302     HTML     17K 
 9: EX-31.2     Certification -- Sarbanes-Oxley Act - Sect. 302     HTML     17K 
10: EX-32.1     Certification -- Sarbanes-Oxley Act - Sect. 906     HTML      9K

EX-10.35 — Material Contract

This Exhibit is an HTML Document rendered as filed. [ Alternative Formats ]

C: C: C:

Exhibit 10.35

AMENDMENT NO. 1

EMPLOYMENT AGREEMENT

THIS AMENDMENT NO. 1 (“Amendment No. 1”) to the EMPLOYMENT AGREEMENT (the “Agreement”) by and between Frank J. Luppino (the “Executive”) and Anika Therapeutics, Inc., a Massachusetts corporation (the “Corporation”), dated as of September 10, 2009, is made this 8th day of December, 2010.

RECITALS

WHEREAS the Corporation and the Executive are parties to the Agreement;

AND WHEREAS, the Corporation and the Executive desire to amend the Agreement as set forth herein.

NOW, THEREFORE, in consideration of the mutual covenants and agreements herein contained and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows:

1. Section 6(a)(i)(A) of the Agreement is hereby amended by adding the following at the end thereof:

“(C) Notwithstanding the foregoing, if the Date of Termination occurs prior to a Change in Control, payment shall be made in substantially equal installments in accordance with the Company’s payroll practice over 18 months, but amounts shall be increased after the Change in Control to reflect the higher level of severance provided by this Section 6.”

2. Except as set forth above, all terms of the Agreement shall remain in full force and effect.

IN WITNESS WHEREOF the parties have executed this Amendment No. 1.

	ANIKA THERAPEUTICS, INC.


	BY:	/s/ *Charles H. Sherwood*



	/s/ *Frank J. Luppino*
	Frank J. Luppino

Dates Referenced Herein and Documents Incorporated by Reference

This ‘10-K’ Filing	Date	Other Filings

Filed on:	3/16/11
For Period End:	12/31/10
	9/10/09	8-K
		List all Filings

2 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 4/26/21  Anika Therapeutics, Inc.          10-K/A     12/31/20  100:10M                                    Globenewswire Inc./FA
 3/05/21  Anika Therapeutics, Inc.          10-K       12/31/20  105:11M                                    Globenewswire Inc./FA

↑Top

Filing Submission 0001157523-11-001610 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)